GlassScriptPhysician profile
Sayf Altabaqchali
NPI 1902105463
$36,467.35
in general payments reported to CMS, 2019-2025
42 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $2,463 · 2021: $22K · 2022: $3,452 · 2023: $3,365 · 2024: $2,828 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980 · Travel and Lodging: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.64 |
| Travel and Lodging | $2,889.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23,522.10 | 2021-2025 | Corevalve Evolut R, Hawkone |
| Boston Scientific Corporation | $2,402.23 | 2019-2024 | Ekosonic, Varithena Administration Pack, Watchman Access System |
| Medtronic Vascular, INC. | $1,357.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,202.59 | 2019-2025 | |
| Medical Device Business Services, INC. | $1,030.46 | 2024 | Carto 3 |
| Abiomed | $1,019.54 | 2020-2025 | Impella |
| Edwards Lifesciences Corporation | $834.96 | 2022 | |
| W. L. Gore & Associates, INC. | $798.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $563.70 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $476.45 | 2019-2024 | Brilinta |
| Janssen Pharmaceuticals, INC | $405.13 | 2019-2024 | Xarelto |
| Abbott Laboratories | $301.66 | 2019-2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.94 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $272.27 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.22 | 2019-2025 | Lifevest |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $221.67 | 2019-2025 | |
| Philips North America LLC | $134.81 | 2022-2025 | Ecc Solutions |
| Sanofi-Aventis U.S. LLC | $132.48 | 2019-2023 | |
| Amarin Pharma, INC. | $127.25 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $119.32 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $105.28 | 2023-2025 | Opsumit, Uptravi |
| Inari Medical, INC. | $102.89 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ancora Heart, INC. | $102.58 | 2022 | |
| Vifor Pharma, INC. | $87.69 | 2019 | |
| Amgen INC. | $78.43 | 2019-2020 | |
| Penumbra, INC. | $76.24 | 2021 | |
| United Therapeutics Corporation | $50.14 | 2024-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $41.78 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Biosense Webster, INC. | $40.28 | 2025 | Nuvision Ice Catheter |
| Corcept Therapeutics | $37.75 | 2025 | Korlym |
| Shockwave Medical, INC | $34.33 | 2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Regeneron Healthcare Solutions, INC. | $32.90 | 2019-2020 | |
| Novo Nordisk INC | $31.30 | 2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals, LTD. | $28.97 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $27.81 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $23.88 | 2024 | Amvuttra |
| Inspire Medical Systems, INC. | $23.81 | 2024 | Inspire |
| Teleflex LLC | $19.96 | 2024 | Supercross |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2022 | |
| Astellas Pharma US INC | $15.42 | 2020 | |
| Esperion Therapeutics, INC. | $15.12 | 2024 | Nexletol |
| Scpharmaceuticals INC. | $14.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayf Altabaqchali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.